Technical Analysis for OMER - Omeros Corporation

Grade Last Price % Change Price Change
grade C 16.89 -4.68% -0.83
OMER closed down 4.68 percent on Friday, March 22, 2019, on 63 percent of normal volume. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Very Strong Down Up Up
See historical OMER trend table...

Date Alert Name Type % Chg
Mar 22 Fell Below 200 DMA Bearish 0.00%
Mar 22 Slingshot Bullish Bullish Swing Setup 0.00%
Mar 22 Overbought Stochastic Strength 0.00%
Mar 21 Overbought Stochastic Strength -4.68%
Mar 20 Upper Bollinger Band Walk Strength -3.82%
Mar 20 Overbought Stochastic Strength -3.82%
Mar 20 Upper Bollinger Band Touch Strength -3.82%
Mar 19 Crossed Above 200 DMA Bullish -3.82%
Mar 19 Expansion Breakout Bullish Swing Setup -3.82%
Mar 19 Above Upper BB Strength -3.82%

Older signals for OMER ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Omeros Corporation, a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing products targeting inflammation, coagulopathies, and disorders of the central nervous system. The company derives product candidates from its proprietary PharmacoSurgery platform that is designed to enhance clinical outcomes of patients undergoing ophthalmological, arthroscopic, urological, and other surgical and medical procedures. The company's product candidates include OMS302, which has completed two Phase III clinical trials for use during intraocular lens replacement surgery, including cataract and other lens replacement surgery; OMS103HP that is in Phase III program for use during arthroscopic procedures comprising partial meniscectomy surgery; and OMS201, which has completed Phase I/Phase II studies for use during urological procedures, including ureterscopy for removal of ureteral or renal stones. Its clinical programs also consist of OMS824, which is in Phase I clinical trial for the treatment of cognitive disorders, including schizophrenia; and OMS405 that is in Phase II clinical trial for the treatment and prevention of addiction to substances of abuse. The company's preclinical product development programs comprise OMS721 for hemolytic uremic syndrome, paroxysmal nocturnal hemoglobinuria, wet age-related macular degeneration, ischemia-reperfusion injury, and transplant-related complications; OMS527 for addictions and compulsive disorders, and movement disorders; and OMS616 for surgical and traumatic bleeding. In addition, it is developing G protein-coupled receptors (GPCR) programs for multiple disorders. Omeros Corporation was incorporated in 1994 and is based in Seattle, Washington.
Medicine Health Biopharmaceutical Medical Specialties Surgery Inflammation Clinical Trial Disorders Schizophrenia Wet Age Related Macular Degeneration Ophthalmology Clinical Research Urology Cataract Movement Disorders Paroxysmal Nocturnal Hemoglobinuria Surgical Specialties Cognitive Disorders Arthroscopy Hemolytic Uremic Syndrome
Is OMER a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 27.0
52 Week Low 10.3
Average Volume 717,260
200-Day Moving Average 17.1057
50-Day Moving Average 14.4178
20-Day Moving Average 15.9555
10-Day Moving Average 16.667
Average True Range 0.708
ADX 51.8
+DI 30.6305
-DI 11.7752
Chandelier Exit (Long, 3 ATRs ) 15.816
Chandelier Exit (Short, 3 ATRs ) 15.924
Upper Bollinger Band 18.0278
Lower Bollinger Band 13.8832
Percent B (%b) 0.73
BandWidth 25.975996
MACD Line 0.8491
MACD Signal Line 0.7663
MACD Histogram 0.0828
Fundamentals Value
Market Cap 756.72 Million
Num Shares 44.8 Million
EPS -1.47
Price-to-Earnings (P/E) Ratio -11.49
Price-to-Sales 11.55
Price-to-Book 0.00
PEG Ratio -0.13
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 18.39
Resistance 3 (R3) 18.51 18.12 18.14
Resistance 2 (R2) 18.12 17.74 18.07 18.06
Resistance 1 (R1) 17.51 17.51 17.32 17.39 17.97
Pivot Point 17.12 17.12 17.03 17.07 17.12
Support 1 (S1) 16.51 16.74 16.32 16.39 15.81
Support 2 (S2) 16.12 16.51 16.07 15.72
Support 3 (S3) 15.51 16.12 15.64
Support 4 (S4) 15.39